


10/511040
 DT04 Rec'd PCT/PTO 12 OCT 2004

In the Claims:

1. (original) Compounds of formula:



in which:

- R_1 represents hydrogen or a (C₁-C₄)alkyl;
- R_2 represents:
 - a (C₃-C₇)alkyl group,
 - an indan-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, said groups being unsubstituted or substituted by a halogen atom and/or a methyl group;
 - a saturated, single-nitrogen heterocyclic radical of 5 to 7 atoms, the nitrogen atom being substituted by a (C₁-C₄)alkyl, benzyl, (C₁-C₃)alkoxycarbonyl or (C₁-C₄)alkanoyl group;
 - a group NR₉R₁₀;
 - a group (CH₂)_nR₁₁, CH(CH₃)R₁₁, (CH₂)_mN(CH₃)R₁₁;
 - a C₃-C₁₂ nonaromatic carbocyclic radical, unsubstituted or substituted one or more times by a methyl group;
- or R_1 and R_2 together with the nitrogen atom to which they are attached form either a piperazin-1-yl radical substituted in position 4 by a phenyl or benzyl group, or a piperidin-1-yl radical disubstituted in position 4 by a phenyl or benzyl group and by a (C₁-C₄)alkyl or (C₁-C₃)alkanoyl group; the phenyl or benzyl group substituents on the piperazin-1-yl radical or the piperidin-1-yl radical being unsubstituted or substituted by a halogen atom and/or a methyl group;
- R_3 , R_4 , R_5 , R_6 , R_7 and R_8 represent each independently of one another a hydrogen or halogen atom or a (C₁-C₆)alkyl, (C₁-C₆)alkoxy or trifluoromethyl group;
- R_9 and R_{10} together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms containing or not containing a second heteroatom selected from O and N, said radical being

unsubstituted or substituted one or more times by a (C₁-C₄)alkyl, hydroxyl or (C₁-C₄)alkoxy group;

- R₁₁ represents:
 - a phenyl which is unsubstituted or substituted by one or more substituents selected from a halogen atom and a methyl group;
 - a heteroaryl radical of 6 to 10 atoms containing one or more nitrogen atoms;
 - n represents 1, 2 or 3;
 - m represents 0, 2 or 3;
- and their salts, their solvates and their hydrates.


2. **(original)** A compound according to claim 1 of formula (I) in which:

- R₁ represents a hydrogen atom or a (C₁-C₄)alkyl group;
 - R₂ represents a group NR₉R₁₀ or a nonaromatic C₃-C₁₂ carbocyclic radical which is unsubstituted or substituted one or more times by a methyl group;
 - R₃, R₄, R₅, R₆, R₇ and R₈ represent each independently of one another a hydrogen or halogen atom or a (C₁-C₆)alkyl, (C₁-C₆)alkoxy or trifluoromethyl group;
 - R₉ and R₁₀ together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms, containing or not containing a second heteroatom selected from O and N, said radical being unsubstituted or substituted one or more times by a (C₁-C₄)alkyl group;
- and their salts, their solvates and their hydrates.

3. **(currently amended)** ~~Compounds~~ A compound according to claim 1 ~~or claim 2~~ of formula (I) in which:


- R₁ represents a hydrogen atom; and/or
- R₂ represents a group selected from piperidin-1-yl, pyrrolidin-1-yl, cyclohexyl, spiro[5.5]undecanyl and 1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl; and/or
- at least one of the substituents R₃, R₄ and R₅ represents a halogen atom or a trifluoromethyl group; and/or
- at least one of the substituents R₆, R₇ and R₈ represents a halogen atom.

4. **(currently amended)** A process for preparing a compound of formula (I) according to claim 1 wherein ~~any one of claims 1 to 3, characterized in that~~ a functional derivative of terphenylic acid of formula:



in which R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are as defined for a compound of formula (I) in claim 1 is treated with an amine of formula HNR_1R_2 (III) in which R_1 and R_2 are as defined for a compound of formula (I) in claim 1.

5. **(original)** Compounds of formula:



in which R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are as defined for a compound of formula (I) in claim 1 and R represents a hydrogen atom or a $(\text{C}_1\text{-C}_4)$ alkyl group, on condition that R_3 , R_4 , R_5 , R_6 , R_7 and R_8 are not simultaneously hydrogen, and on condition that, when R_4 , R_5 , R_7 and R_8 represent hydrogen, R_3 and R_6 do not simultaneously represent a fluorine atom in meta position, or a methoxy group in meta or para position, and on condition that when R_5 and R_8 represent hydrogen R_3 , R_4 and R_5 , R_6 do not simultaneously represent 3,4-dimethoxy groups.

6. **(original)** A compound according to claim 5 of formula (IIa) in which:

- R_3 is in position 4 and represents a halogen atom or a trifluoromethyl group;
- R_6 is in position 2 and represents a hydrogen or halogen atom;
- R_7 is in position 4 and represents a halogen atom;
- R_4 , R_5 and R_8 are hydrogen.

7. (cancelled)

8. (currently amended) A pharmaceutical composition ~~characterized in that it~~ which comprises a compound of formula (I) according to claim 1 ~~any one of claims 1 to 3~~, or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.

9. (currently amended) ~~The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended~~ A method for treating any disease involving the CB₁ cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

10. (currently amended) ~~The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended~~ A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

11. (new) A compound according to claim 2 of formula (I) in which:

- R₁ represents a hydrogen atom or a (C₁-C₄)alkyl group;
- R₂ represents a group NR₉R₁₀ or a nonaromatic C₃-C₁₂ carbocyclic radical which is unsubstituted or substituted one or more times by a methyl group;
- R₃, R₄, R₅, R₆, R₇ and R₈ represent each independently of one another a hydrogen or halogen atom or a (C₁-C₆)alkyl, (C₁-C₆)alkoxy or trifluoromethyl group;
- R₉ and R₁₀ together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms, containing or not containing a second heteroatom selected from O and N, said radical being unsubstituted or substituted one or more times by a (C₁-C₄)alkyl group;

and their salts, their solvates and their hydrates.

12. (new) A pharmaceutical composition which comprises a compound of formula (I) according to claim 2 or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.

13. **(new)** A pharmaceutical composition which comprises a compound of formula (I) according to claim 3 or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.
14. **(new)** A pharmaceutical composition which comprises a compound of formula (I) according to claim 11 or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.
15. **(new)** A method for treating any disease involving the CB₁ cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.
16. **(new)** A method for treating any disease involving the CB₁ cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.
17. **(new)** A method for treating any disease involving the CB₁ cannabinoid receptor which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 11.
18. **(new)** A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.
19. **(new)** A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.
20. **(new)** A method for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 11.